Cefpodoxime Proxetil Tablets Rx
Generic Name and Formulations:
Cefpodoxime proxetil 100mg, 200mg; tabs.
Various generic manufacturers
Indications for Cefpodoxime Proxetil Tablets:
Susceptible mild to moderate infections including acute otitis media, acute bacterial exacerbations of chronic bronchitis, acute maxillary sinusitis, pharyngitis/tonsillitis, acute community-acquired pneumonia, urinary tract, skin and skin structures; cervical, anorectal (females only) and urethral gonorrhea.
Take tabs with food. ≥13yrs: Pneumonia: 200mg every 12hrs for 14 days. Bronchitis, sinusitis: 200mg every 12hrs for 10 days. Pharyngitis/tonsillitis: 100mg every 12hrs for 5–10 days. Skin and skin structures: 400mg every 12hrs for 7–14 days. UTI: 100mg every 12hrs for 7 days. Uncomplicated gonorrhea: 200mg once as a single dose. Renal failure or hemodialysis: see full labeling.
Use susp. <2 months: not recommended. 2 months–12yrs: Acute otitis media: 5mg/kg (max 200mg) every 12hrs for 5 days. Pharyngitis/tonsillitis: 5mg/kg (max 100mg) every 12hrs for 5–10 days. Sinusitis: 5mg/kg (max 200mg) every 12hrs for 10 days.
Penicillin or other allergy. Labor & delivery. Pregnancy (Cat.B). Nursing mothers: not recommended.
Antacids, H2 antagonists, oral anticholinergics may decrease efficacy. Potentiated by probenecid. Avoid concomitant diuretics, other nephrotoxic drugs. May cause false (+) direct Coomb's test.
GI upset, abdominal pain, headache, rash, anaphylaxis.
Formerly known under the brand name Vantin.
Clinical Pain Advisor Articles
- Analyzing Coverage of Nonpharmacologic Treatments for Low Back Pain
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Predicting the Magnitude of Placebo Analgesia in Chronic Pain
- Dsuvia Gains FDA Approval: We Want to Hear Your Thoughts
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- Daily Alcohol Use May Drive Chronic Pain in Adults With HIV
- Tools to Address the Opioid Crisis
- AHA/ACC Release Updated Guidelines for Cholesterol Management
- Women Fed Soy Formula as Infants More Likely to Experience Menstrual Pain